14,198 IDEXX Laboratories, Inc. $IDXX Shares Sold by Ethic Inc.

Ethic Inc. reduced its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 59.2% during the third quarter, Holdings Channel reports. The institutional investor owned 9,795 shares of the company’s stock after selling 14,198 shares during the period. Ethic Inc.’s holdings in IDEXX Laboratories were worth $5,115,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently made changes to their positions in IDXX. J.Safra Asset Management Corp bought a new stake in IDEXX Laboratories during the 2nd quarter worth approximately $25,000. Elevation Wealth Partners LLC lifted its holdings in IDEXX Laboratories by 188.2% during the second quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock valued at $26,000 after purchasing an additional 32 shares in the last quarter. Pension & Wealth Management Advisors Inc. bought a new position in shares of IDEXX Laboratories in the third quarter worth approximately $29,000. Arlington Trust Co LLC boosted its position in shares of IDEXX Laboratories by 46.3% in the second quarter. Arlington Trust Co LLC now owns 60 shares of the company’s stock worth $32,000 after purchasing an additional 19 shares during the period. Finally, Bell Investment Advisors Inc boosted its position in shares of IDEXX Laboratories by 45.5% in the third quarter. Bell Investment Advisors Inc now owns 64 shares of the company’s stock worth $33,000 after purchasing an additional 20 shares during the period. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Stock Up 4.5%

NASDAQ IDXX opened at $706.65 on Tuesday. IDEXX Laboratories, Inc. has a 12 month low of $500.61 and a 12 month high of $769.98. The company has a current ratio of 1.19, a quick ratio of 0.87 and a debt-to-equity ratio of 0.16. The stock has a market cap of $55.68 billion, a PE ratio of 47.20 and a beta of 1.55. The stock’s 50 day moving average is $549.78 and its 200 day moving average is $573.40.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Monday, November 2nd. The company reported $3.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.71 by $0.25. The business had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.19 billion. IDEXX Laboratories had a net margin of 25.36% and a return on equity of 71.04%. The company’s revenue was up 9.9% on a year-over-year basis. During the same period last year, the firm posted $3.22 EPS. Research analysts predict that IDEXX Laboratories, Inc. will post 15.05 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

IDXX has been the subject of a number of analyst reports. UBS Group increased their price objective on shares of IDEXX Laboratories from $627.00 to $700.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 3rd. The Goldman Sachs Group began coverage on shares of IDEXX Laboratories in a report on Friday, October 16th. They issued a “buy” rating and a $740.00 target price for the company. Jefferies Financial Group dropped their target price on shares of IDEXX Laboratories from $795.00 to $705.00 and set a “buy” rating for the company in a report on Tuesday, October 20th. Weiss Ratings upgraded IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th. Finally, Barclays decreased their price target on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a report on Tuesday, August 11th. Seven equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $717.27.

Insider Activity

In other IDEXX Laboratories news, Director Lawrence D. Kingsley sold 2,203 shares of the business’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $532.08, for a total value of $1,172,172.24. Following the sale, the director owned 9,568 shares in the company, valued at $5,090,941.44. The trade was a 18.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Sharon E. Underberg sold 8,906 shares of the stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $688.59, for a total transaction of $6,132,582.54. Following the transaction, the executive vice president directly owned 7,169 shares of the company’s stock, valued at $4,936,501.71. This trade represents a 55.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 41,428 shares of company stock valued at $28,567,934 in the last quarter. Company insiders own 0.79% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories develops and sells diagnostic, technology and software products for veterinary, livestock and water-testing markets. Its veterinary offerings include in-clinic diagnostic instruments and tests, reference laboratory services, digital imaging and practice-management software that help veterinary professionals assess animal health and manage their practices.

The company also provides diagnostic tests and related services for livestock and poultry, as well as products used to monitor water quality.